Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0.028).

in patients with symptomatic oral lichen planus (OLP). The 0.50 mg cohort was treated over a four-week period, with Week 4 serving as the primary endpoint. Week 6 data reflect follow-up ...

LP-310 is being developed as a non-steroidal, locally delivered treatment for oral lichen planus, a chronic inflammatory condition with no FDA-approved therapies.